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Chlamydia infection depends on a functional
MDM2-p53 axis
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Chlamydia, a major human bacterial pathogen, assumes effective strategies to protect
infected cells against death-inducing stimuli, thereby ensuring completion of its develop-
mental cycle. Paired with its capacity to cause extensive host DNA damage, this poses a
potential risk of malignant transformation, consistent with circumstantial epidemiological
evidence. Here we reveal a dramatic depletion of p53, a tumor suppressor deregulated in
many cancers, during Chlamydia infection. Using biochemical approaches and live imaging of
individual cells, we demonstrate that p53 diminution requires phosphorylation of Murine
Double Minute 2 (MDM2; a ubiquitin ligase) and subsequent interaction of phospho-MDM2
with p53 before induced proteasomal degradation. Strikingly, inhibition of the p53–MDM2
interaction is sufficient to disrupt intracellular development of Chlamydia and interferes with
the pathogen’s anti-apoptotic effect on host cells. This highlights the dependency of the
pathogen on a functional MDM2-p53 axis and lends support to a potentially pro-carcinogenic
effect of chlamydial infection.
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T
he tumour suppressor p53, the ‘guardian of the genome’,
is modulated in response to cellular stress, including
DNA damage, osmotic shock, ribonucleotide depletion,
deregulated oncogene expression and also by specific pathogenic
bacteria1,2. Activation of p53 initiates a suite of signalling
cascades that lead to transient cellular responses (for example,
cell cycle arrest and DNA repair) or to terminal cell fates (for
example, differentiation, apoptosis or senescence), depending on
the nature and degree of the signal initiated3.
Chlamydia trachomatis is the most common cause of sexually
transmitted bacterial infection in humans and the leading cause
of preventable blindness worldwide4. If left untreated, infection in
women can lead to pelvic inflammatory disease, causing chronic
pelvic pain and even infertility. In addition, positive correlations
between C. trachomatis infection and invasive cervical cancer
(ICC) in human papillomavirus (HPV)-positive women suggest
that Chlamydia can act as co-factor for squamous cell
transformation5–7, although the molecular mechanism for this
correlation is unclear.
Depending on the infection stage, Chlamydia can induce host
cell death or actively inhibit apoptosis8. Initial observations
demonstrated a profound resistance of C. trachomatis-infected
HeLa cells to a range of apoptotic stimuli9, a property that was
shared with other pathogenic Chlamydia species10. Our recent
finding that cells cleared of Chlamydia infection exhibit reduced
p53 binding to the promoter of the cell cycle checkpoint regulator
p21 (ref. 11), together with the central role of p53 in modulating
the cellular stress response, notably apoptosis, prompted us to
investigate the consequences of Chlamydia infection on cellular
p53 levels.
Here we find that p53 is proteolytically degraded from 24hours
post-infection (h p.i.) with various Chlamydia species in response to
activation of the classical p53–MDM2 interaction axis. Further, we
find that pharmacological inhibition of this interaction is sufficient
to inhibit both the intracellular development of the pathogen and
re-sensitize the infected host cells to apoptotic stimuli.
Results
Chlamydia infection induces the degradation of p53. Western
immunoblotting of HeLa cells infected with Chlamydia tracho-
matis L2 (CTL2) revealed a striking reduction in total cellular p53
protein starting from 24 h p.i., with a further reduction to nearly
non-detectable levels between 36 and 48 h p.i. (Fig. 1a). The
Chlamydia-induced p53 degradation was observed irrespective of
the cell lysis and protein sample preparation procedure applied
(Laemmli, 8M urea or RIPA buffer; Supplementary Fig. 1a,b),
excluding proteolytic artefacts12. Also, the degraded protein was
confirmed to be tumour-suppressor p53 using specific RNA
interference oligonucleotides (Supplementary Fig. 1c).
Previous studies have demonstrated that population-averaged
analyses such as immunoblotting can mask true dynamic
signalling responses to stress13,14. Furthermore, we sought to
circumvent the necessary lysis steps inherent in these protocols as
there is currently significant controversy surrounding the actions
of chlamydial proteases following cell lysis12. We therefore
analysed p53 dynamics in intact cells using an MCF7 reporter cell
line expressing pMT-p53-Venus and pEF1a-mCherry-53BP1.
These cells present spontaneous asynchronous pulses in the
fluorescent p53-Venus signal over time15. Cells were infected with
CTL2 and examined by time-lapse videomicroscopy from 24 to
48 h p.i. Strikingly, although p53-Venus oscillations (p53 pulses)
were observed in uninfected cells, infected cells (identified by
their large Chlamydia-filled inclusions) presented a rapid and
sustained reduction of p53-Venus signal from 24 to 48 h p.i.,
concurrent with an increase in inclusion size (Fig. 1b–d;
Supplementary Movie 1). As the expression of this p53-Venus
reporter is under the control of a constitutive metallothionein
(MT) promoter, this observation suggests that the decrease in
cellular p53 observed in Fig. 1a must reflect proteolytic activity
rather than transcriptional regulation.
Regulation of p53 degradation is mediated by Murine Double
Minute 2 (MDM2). Following activation, MDM2 binds and
ubiquitinates p53, leading to its translocation to the cytosol and
proteasomal degradation16. MDM2 is phosphorylated by AKT at
Ser-166/186, both of which are located within the RXRXXS/T
consensus motifs for AKT kinase. The phosphorylation of MDM2
at Ser-166/186 promotes its nuclear localization and its interaction
with p300, a transcriptional co-activator that forms a complex with
MDM2 and promotes p53 degradation17–19. To monitor MDM2
activation, we carried out western immunoblotting of Chlamydia-
infected protein samples using an anti-phospho-MDM2 (Ser166)
antibody. From 10h p.i. an elevation in phosphorylated MDM2
was observed, suggesting that this might be an essential step
involved in p53 degradation in Chlamydia-infected cells (Fig. 2a).
Notably, western immunoblotting of the same samples using
antibodies to detect total MDM2 levels showed no change
following infection. Inhibiting proteasomal activity with the cell
permeable proteasome inhibitors MG132 and lactacystin20–also a
known inhibitor of the chlamydial protease-like activity factor
(CPAF)–rescued p53 protein levels (Fig. 1e), indicating the
involvement of the proteasome in Chlamydia-induced p53
degradation. To exclude artificial post-lysis degradation of p53
by CPAF, we also monitored cleavage of keratin-8 and vimentin,
two recognized post-lysis CPAF targets12,21. No evidence of
keratin-8 or vimentin proteolysis was observed at 48 h p.i. (Fig. 1e)
thus validating our lysis method.
To dissect the link between Chlamydia-induced p53
degradation and MDM2 phosphorylation, we used established
pharmacological inhibitors as they offer the capacity to rapidly
and specifically target key molecular players. Nutlins are
cis-imidazoline analogues that inhibit the interaction between
phospho-MDM2 and p53 (ref. 22). Similarly, the small-molecule
inhibitor RITA (reactivation of p53 and induction of tumour cell
apoptosis) binds p53 and thereby also prevents its interaction
with MDM2 and the subsequent degradation of p53 (ref. 23).
Cells were infected with CTL2 for 48 h, treated with Nutlin3a or
RITA at the indicated concentrations from 12 h p.i., and subjected
Figure 1 | Chlamydia induces p53 degradation. (a) Western blotting analysis showing progressive degradation of total p53 protein between 24
and 48 h p.i. in CTL2-infected whole-cell lysates (MOI¼ 1). Chlamydial Hsp60 and b-actin served as infection and loading controls, respectively.
(b) Representative time-lapse microscopy images of p53-Venus-expressing cells infected with CTL2 (MOI¼0.5) from 24 to 40h p.i. Nuclei from infected
and uninfected cells are presented as montages as indicated. (c) Individual cells were tracked and the average nuclear Venus fluorescence (in green)
measured. Normalized trajectories of p53-Venus levels are shown. Vertical dashed line indicates time of cell division. Scale bar, 20 mm. (d) The fraction of
cells showing no pulse, 1 or 2 pulses or more than 3 pulses between 24 and 48 h p.i. The frequency of p53 pulses from 460 infected or uninfected cells
were quantified. Error bars present the standard error of the proportion. (e) Western blotting showing decreased degradation of total p53 and non-cleavage
of keratin 8 and vimentin in whole-cell lysates prepared from cells infected with CTL2 (MOI¼ 1) for 48 h and treated with the proteasome inhibitors
lactacystin or MG132 (150 mM) from 47h p.i. Chlamydial Major Outer Membrane Protein (MOMP) and b-actin served as infection and loading controls,
respectively. Full blots for a and e are shown in Supplementary Fig. 7.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6201
2 NATURE COMMUNICATIONS | 5:5201 | DOI: 10.1038/ncomms6201 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
to western immunoblotting. The inhibitors markedly reduced the
degree to which p53 was degraded, whereas levels of
phosphorylated MDM2, total MDM2 and bacterial Hsp60
protein remained unchanged (Fig. 2b). Further, time-lapse
videomicroscopy demonstrated that 5 mM Nutlin3a added at
24 h p.i. was sufficient to rescue the pulses in p53-Venus, despite
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infection with CTL2 (Fig. 2c). Interestingly, although infected
cells presented regular pulses in p53-Venus signal with Nutlin3a
treatment, uninfected cells presented a sustained p53-Venus
signal (Supplementary Movie 2). Treatment with the bacterial
protein synthesis inhibitor chloramphenicol (CAM, 10–
100mgml 1) from 24 h p.i. was sufficient to inhibit inclusion
expansion24, however, it was not sufficient to rescue the p53-
Venus pulses (Fig. 2c and Supplementary Movie 3) or prevent
phosphorylation of MDM2 and degradation of p53
(Supplementary Fig. 2).
There is considerable controversy surrounding the roles played
by secreted bacterial proteases during chlamydial infection
and the associated protein degradation phenotypes observed25.
Treatment of Chlamydia-infected cells with CAM is sufficient
to reverse a number of cellular phenotypes induced upon
infection26–28, presumably reflecting an inability to maintain
sufficient intracellular concentrations of secreted bacterial effector
molecules following application of the agent. Indeed, time-lapse
videomicroscopy of Chlamydia-infected cells treated with
10 mgml 1 CAM from 24 h p.i. and imaged from 48 to 88 h
p.i. continued to present a lack of p53-Venus pulses
(Supplementary Movie 4). To examine the possible role played
by CPAF in this process, a published cell permeable CPAF-
specific inhibitor peptide29 was employed in conjunction with
time-lapse videomicroscopy. As reported previously, addition of
the CPAF-inhibitor peptide from 12 or 24 h p.i. led to rapid
induction of non-apoptotic cell death in CTL2-infected cells,
severely attenuating the duration that videomicroscopy could be
performed29. In spite of this, no p53 pulses were observed from
24–40 h p.i. in Chlamydia-infected cells cultured in the presence
of the inhibitor peptide, whereas p53 pulses were still readily
observed in uninfected cells (Supplementary Movie 5).
Chlamydia requires functional interaction of MDM2 with p53.
A moderate reduction in the expansion of inclusions in infected
cells treated with 5 mM Nutlin3a was noted in the time-lapse
experiments (compare Supplementary Movies 1 and 2). This
prompted us to investigate the consequences of Nutlin3a treat-
ment on the formation of infectious CTL2 progeny. Cells were
infected with CTL2 for 24 h to establish infection and then treated
with increasing concentrations of Nutlin3a or RITA for a further
24 h. The cells were then lysed and the lysates used to infect a
second population of HeLa cells for 24 h. Cells were fixed,
immunolabelled and the number of resulting inclusions quanti-
fied. In parallel, the impact of Nutlin3a or RITA on inclusion
size and number as well as the number of host cell nuclei was
monitored in the primary infection. Strikingly, although there was
little significant impact upon inclusion size or number in the
primary infection following Nutlin3a or RITA treatment, there
was a dramatic, dose-dependent decrease in infectious progeny,
suggesting that the pathogen was unable to complete its normal
developmental cycle (Fig. 3a).
Chlamydial development is characterized by the reversible
transition from an electron-dense elementary body (EB) to a
larger, non-infectious replicative reticulate body (RB). During the
later stages of the infection cycle, the replicating RBs transform
back into infectious EBs before host cell lysis or extrusion of the
inclusion. Ultrastructural analysis by transmission electron
microscopy of HeLa cells infected for 48 h with CTL2 in the
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Figure 2 | Chlamydia-induced degradation of p53 is mediated by
phosphorylation of MDM2. (a) Western blotting analysis showing a
progressive increase of P-MDM2 (S166) compared with total MDM2
between 10 and 48h p.i. in CTL2 (MOI¼ 1)-infected whole-cell lysates.
Chlamydial Hsp60 and b-actin served as infection and loading controls,
respectively. (b) Western blotting showing decreased degradation of total
p53 in whole-cell lysates prepared from cells infected with CTL2 (MOI 1) for
48h and treated with the inhibitors Nutlin3a or RITA. Chlamydial Hsp60 and
b-actin served as infection and loading controls, respectively. Full blots for a
and b) are shown in Supplementary Fig. 7. (c) The fraction of cells showing
no pulse, 1 or 2 pulses or more than 3 pulses between 24 and
48h p.i. was quantified following treatment with Nutlin3a or chloramphenicol
(CAM). The frequency of p53 pulses from460 infected or uninfected cells
was quantified. Error bars present the standard error of the proportion.
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presence or absence of 5 or 10mM Nutlin3a from 24 h p.i.
revealed that Nutlin3a did not induce major morphological or
structural changes in inclusion or bacterial membranes, nor were
enlarged RBs, often referred to as aberrant bodies, observed
(Fig. 3b). However, there was a highly significant reduction in the
proportion of EBs coupled with a concurrent increase in the
proportion of intermediate bodies (IBs)–RBs in the process of
retransformation to EBs–characterized by their size and compact
nucleoids (Fig. 3b,c). Similar observations were made in
RITA-treated cells (Supplementary Fig. 3). This suggests that a
functional MDM2–p53 interaction is necessary for the proper
formation of infectious EBs.
Degradation of p53 is conserved among pathogenic
Chlamydiae. The primary site of CTL2 infection is the urogenital
system. To examine the impact of CTL2 infection upon p53 in
cells of this system, human primary mesenchymal cells were
prepared from fallopian tubes surgically removed from patients
undergoing procedures for benign gynaecological disease, as
described previously30. These primary cells were infected with
CTL2 at multiplicity of infection (MOI)¼ 1 and treated with
Nutlin3a or CAM from 24 to 48 h p.i. The samples were then
fixed and prepared for immunofluorescence microscopy using
antibodies against p53 and CTL2 (Fig. 4a). Confocal analysis
confirmed that while around 40% of non-infected cells presented
a detectable p53 signal in the nucleus, this proportion decreased
significantly to less than 10% upon infection, in congruence with
our observations in HeLa and MCF7 cells. Similarly, the decrease
in p53 signal could be rescued following treatment with 10 mM
Nutlin3a but not with 10 mgml 1 CAM (Fig. 4b). As in HeLa
cells, CTL2 infection did not influence total cellular MDM2 levels
of primary fallopian tube mesenchymal cells (Supplementary
Fig. 4). Western immunoblotting of primary fallopian tube
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***Po0.001, one-way analysis of variance with Bonferroni post-hoc test. (b) Representative transmission electron micrographs of infected cells 48 h p.i.,
with or without Nutlin3a from 24 h p.i. Scale bars, 5mm. Insets present high-resolution images of the indicated region. (c) The relative proportion of EBs,
RBs and IBs, quantified from 5 to 6 electron micrographs of three independent experiments. Nutlin3a treatment significantly increased the proportion of IBs,
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mesenchymal cells infected with CTL2 and treated with Nutlin3a
confirmed that Chlamydia-induced p53 degradation was
dependent upon a functional p53–MDM2 interaction (Fig. 4c).
CAM treatment was not sufficient to prevent degradation of p53
in primary mesenchymal cells from the fallopian tube (Fig. 4c).
These observations in primary cells are in accordance with the
western immunoblotting and live cell microscopy data of HeLa
cells presented in Fig. 2b,c, Supplementary Movies 2 and 3 and
Supplementary Fig. 2.
To investigate whether or not this phenotype was species-
specific, the impact of infection with C. pneumoniae, C. psittaci,
C. muridarum and C. trachomatis L2 on p53 protein levels in
primary fallopian tube cells was compared. Western immuno-
blotting demonstrated that in all cases infection resulted in a
significant decrease in p53 (Fig. 4d). In contrast, infection with
Simkania negevensis31,32–a primarily environmental bacterial
member of the order of Chlamydiales–did not induce
degradation of p53 (Fig. 4d; Supplementary Fig. 5). This
observation suggests that p53 degradation results from a direct
impact of the invasive Chlamydiaceae upon the host cell rather
than from general, unspecific infection-induced stress.
Loss of p53 contributes to Chlamydia’s anti-apoptotic
influence. Chlamydia-infected cells are profoundly resistant to
apoptosis during the replicative phase of the pathogen’s devel-
opment8. To determine whether the observed p53 degradation
contributes to this apoptosis resistance, HeLa cells at 12 h p.i.
were treated with 20 mM Nutlin3a for 10 h, followed by induction
of apoptosis with 50 ngml 1 tumour necrosis factor-a (TNF-a)
and 10 mgml 1 cycloheximide for 5 h. Cells were fixed and
examined by immunofluorescence microscopy using antibodies
directed against cleaved caspase-3. Although Chlamydia infection
alone conferred significant resistance to TNF-a-induced
apoptosis, inhibition of MDM2-mediated degradation of p53
with Nutlin3a was sufficient to partly reverse this phenotype
(Fig. 4e,f). An alternative readout of apoptosis was applied by
using antibodies directed against cleaved poly-(ADP-ribose)
polymerase (PARP). Again, Nutlin3a treatment of infected cells
partly re-sensitized cells to the pro-apoptotic signal elicited by
TNF-a as monitored by the significant increase in the number of
infected and cleaved PARP-positive cells, thus reinforcing our
observation that recovery of p53 protein levels through inhibition
of the MDM2–p53 interaction impairs the anti-apoptotic effect
induced by Chlamydia (Supplementary Fig. 6). Indeed, we noted
that infected MCF7 p53-Venus reporter cells were also more
sensitive to photodamage during the live-cell imaging
experiments following treatment with Nutlin3a (Supplementary
Movie 2), indicating that they are more sensitive to extracellular
stress stimuli, again reinforcing the connection between the
degradation of p53 and the resistance to apoptosis observed in
Chlamydia-infected cells.
Therefore, MDM2-mediated degradation of p53 in Chlamydia-
infected cells contributes to the anti-apoptotic influence upon the
host cell.
Discussion
In order to complete its unique biphasic developmental cycle,
Chlamydia has developed potent strategies to protect infected
cells against death-inducing stimuli8. The metabolic burden
placed upon the host cell during the replicative phase and the
later stages of chlamydial infection initiates a number of stress-
related signalling pathways, which in turn need to be modulated
by the pathogen to maintain host cell viability, thereby ensuring
the survival of Chlamydia and allowing for a productive
infection33–35. Here we reveal the Chlamydia-induced
degradation of p53, a key molecular node in the cellular stress
response pathway. This degradation was preceded by the
activation of the canonical p53-MDM2 axis and could be
reversed through the application of specific pharmacological
inhibitors of this interaction.
Chlamydia infection has recently been shown to cause
accumulation of double-stranded DNA breaks within the genome
of the host cell while simultaneously interfering with the DNA
damage response, notably activation of the key transducer of
double-stranded DNA break signals, the nuclear protein kinase
ataxia telangiectasia mutated36. Thus, the p53 degradation
phenotype reported here represents another example of how
Chlamydia infection interferes with the host’s genotoxic stress
response. As the p53 degradation phenotype was observed with
all Chlamydia species tested, as well as in the presence of the
bacterial protein synthesis inhibitor CAM, activation of the
MDM2 feedback loop is likely to occur via a host-derived
mechanism. One attractive candidate for this role is the
AKT/PKB serine-threonine kinase. MDM2 associates with AKT
and is phosphorylated at serine residues 166 and 186 following
activation of the kinase (through phosphorylation at residues 308
and 473) or ectopic expression of constitutively active AKT. AKT
itself is activated in response to a variety of cell survival stimuli
via the phosphatidylinositol 3-kinase signalling cascade37,38.
Verbeke et al.39 demonstrated that inhibition of both
phosphatidylinositol 3-kinase activity and AKT expression
renders CTL2-infected cells sensitive to staurosporine-induced
apoptosis. Further, the authors demonstrated that AKT itself was
phosphorylated at serine residue 473 following infection39,
supporting the consideration that this upstream signalling
cascade is instrumental for the degradation phenotype
presented here. In addition, however, the inability of Nutlin3a
treatment to re-sensitize the infected cells to apoptotic stimuli to
the degree seen in uninfected cells strongly suggests that
additional mechanisms are employed by the pathogen40–43.
We show that treatment with Nutlin3a and RITA inhibits the
later stages of the pathogen’s developmental cycle and thereby
blocks the formation of infectious progeny. Precisely, why p53
degradation supports progression of the pathogen’s intracellular
development is unclear. Intriguingly, the accumulated IB
phenotype observed in Nutlin3a-treated cells is distinctive and
remarkably similar to that observed when chlamydial lipooligo-
saccharide synthesis is inhibited with small molecules, although
the agents used in this study share no structural relationship with
Nutlin3a44. Given p53’s central role in cellular metabolism45 and
the dependence of the pathogen upon the host for metabolites,
metabolomic studies under these conditions may prove to be
enlightening.
Finally, given the prominent role of p53 in tumour suppres-
sion, one wonders about the contribution of Chlamydia-induced
p53 degradation to tumourigenesis in the female genital tract.
Indeed, a number of epidemiological studies have linked
Chlamydia infection with several gynaecological cancers, includ-
ing cervical and ovarian cancers46, and carcinogenesis in other
organs47. It is established that infection with HPV is necessary
but not sufficient to induce ICC, as only a small proportion
of women infected with HPV progress to develop ICC48.
This implicates the involvement of additional genetic or
environmental factors including infectious agents that may
contribute to final transformation. Given that C. trachomatis is
the most common sexually transmitted bacterium in humans, it
represents an attractive candidate for such a co-factor. Several
large cohort studies have found a significant correlation between
C. trachomatis infection and an increased risk of ICC
development when adjusted for other factors5,6,49, whereas a
single study opposed these epidemiological findings50. Thus,
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C. trachomatis infection may play a role in confounding
squamous cell ICC in HPV-infected women.
Intriguingly, p53 degradation is an important virulence
mechanism in the infection of cervical cells with oncogenic
HPV strains 16 and 18 (ref. 51). The E6 and E7 open reading
frames of HPV encode oncogenes, of which E7 binds to tumour-
suppressor protein pRB leading to its degradation via the
ubiquitin-proteasome pathway52,53 and E6 forms a complex
with p53 and E6AP, an E3 ubiquitin ligase, promoting p53
degradation via the same pathway54,55. Co-infection with C.
trachomatis might augment the action of the E6 HPV protein by
activating MDM2-dependent degradation of p53 and shift cell
fate further towards transformation.
Our observations with normal human cells derived from the
fallopian tube, which is not a primary site of HPV infection,
further suggest that C. trachomatis could induce severe p53
degradation even in the absence of E6. It has recently been
suggested that a significant proportion of high-grade serous
ovarian cancer originates from the columnar epithelium of the
fallopian tube56–58, which is readily colonized by C. trachomatis
during ascending infections. Intriguingly, p53 loss of function is
a common denominator of nearly all ovarian cancer cases59.
Functional p53 signalling is likely to be an essential response to
the cytotoxic stress triggered in the fallopian tube by
ovulation60. Chronic or recurrent infections with C.
trachomatis could interfere with this protective mechanism.
Hence, our study also lends support for a possible direct role of
C. trachomatis infection in ovarian cancer development.
Although more comprehensive insight is required to
determine the mechanistic contribution of C. trachomatis to
these malignancies, the observation of p53 degradation may be
considered a significant piece of the puzzle.
Methods
Antibodies, cell lines, human tissue samples and reagents. Mouse
monoclonal anti-p53 (DO-1, sc-126, 1:1,000–2,000 for immunoblotting, 1:100 for
immunofluorescence) and rabbit anti-total MDM2 (N-20, sc-813, 1:1,000 for
immunoblotting, 1:100 for immunofluorescence) were purchased from Santa Cruz
Biotechnology Inc.; anti-Chlamydia trachomatis MOMP (ab20881, 1:2,000),
anti-cytokeratin-8 (ab9023, 1:8,000) and anti-vimentin (ab16700, 1:2,000)
antibodies were purchased from Abcam, mouse monoclonal anti-Chlamydia
trachomatis species-specific KK-12 IgG2a, was obtained from David Grayston
(University of Washington, Seattle, WA, USA, 1:10,000), genus-specific rabbit
polyclonal anti-Chlamydia (3-090, 1:100) from Milan Analytica, mouse mono-
clonal anti-C. trachomatis Hsp60 (ALX-804-072-R100, 1:8,000) from Enzo Life
Sciences; rabbit monoclonal anti-cleaved PARP (Asp214, D64E10, 1:400) from Cell
Signaling, mouse monoclonal anti-b-actin (AC-15, 1:4,000–16,000) from Sigma,
rabbit polyclonal anti-cleaved caspase-3 (Asp175, 9661, 1:400) and rabbit poly-
clonal anti-P-MDM2 (S166, 3521S, 1:1,000) were from Cell Signaling. Secondary
antibodies used for immunofluorescence and western blot analyses were Cy3-
linked anti-rabbit (711-165-152, 1:200) and anti-mouse (115-166-072, 1:200), Cy2-
linked anti-mouse (115-225-146, 1:200) and DyLight 488 anti-rabbit (111-485-144,
1:200) from Jackson ImmunoResearch Laboratories, HP-linked ECL anti-rabbit
(NA934, 1:3,000) and HP-linked anti-mouse (NA931, 1:3,000) from Amersham.
HeLa (ATCC CCL-2) and the p53-Venus reporter MCF7 cell lines15 were
maintained in RPMI-1640 medium (52400) from Gibco-Life Technologies (52400)
supplemented with 10% fetal bovine serum (S0115, Biochrom AG). Nutlin3a was
purchased from Sigma (N6287), RITA from Calbiochem (506149), MG132 from
Sigma (C2211) and Lactacystin from Cayman Chemical (CAS 154226-60-5).
CPAF-inhibitor peptide (SLFYSPMVPHFWAELRNHYATSGLKRRRRRRRRR)
and the scrambled control (NFALSHFRLPLSTYKEMPYVSHWAGRRRRRRRRR)
with 495% purity were ordered from Genscript. A dose-dependent reduction in
infectious progeny and induction of cell death, as reported previously61, was used
to confirm its efficacy. RNA interference oligonucleotides siAllstars (scrambled
control) and sip53 (targeting p53, 50-TTGGTGAACCTTAGTACCTAA-30) were
purchased from Qiagen. Hoechst 33342 was purchased from Sigma.
Human fallopian tube tissue samples were provided by the Department of
Gynaecology, Charite´ University Hospital, Campus Virchow Clinic, Berlin,
Germany. Scientific use of the tissue was approved by the Ethics Commission of the
Charite´, Berlin (EA1/002/07) and informed consent was obtained from all subjects.
Fragments were sourced from standard surgical procedures for benign
gynaecological diseases and only anatomically normal pieces were utilized for
subsequent experiments. Primary mesenchymal cells were prepared from these
samples as described previously30 and typically used for infection at passage
numbers six to eight.
Infections with Chlamydiales. We used Chlamydia trachomatis L2 (ATCC
VR-902B), Chlamydia pneumoniae (ATCC VR-1310), Chlamydia muridarum
(ATCC VR-123), Chlamydia psittaci (02DC15) and Simkania negevensis (ATCC
VR-1471) at the indicated MOIs. Cells were infected for 2 h in normal RPMI growth
medium containing 5% fetal bovine serum, 2mM glutamine and 1mM sodium
pyruvate at 35 C. The medium was then replaced with fresh growth medium and
cells were cultured for the indicated times at 35 C. In addition, C. pneumoniae and
C. psittaci inocula were centrifuged at 920 g for 30min onto fresh cell monolayers
and then further incubated under the conditions described above.
Western immunoblotting. Cell monolayers were lysed directly with SDS lysis
buffer (100mM Tris/HCl, pH 6.8, 4% SDS, 20% glycerol, 0.02% bromophenol blue,
200 nM dithiothreitol), where indicated with 8M urea12 or RIPA lysis buffer
(50mM Tris/HCl pH 7.5, 1% Nonidet P-40, 0.1% SDS, 150mM NaCl, 2mM
EDTA). RIPA lysates were incubated for 30min on ice. Cell lysates were boiled
at 95 C for 10min. Equal amounts of protein were separated using
SDS–polyacrylamide gel electrophoresis and immunoblotted as described
previously62.
Time-lapse videomicroscopy. This procedure was conducted on cells seeded onto
glass-bottom 35mm dishes (Mattek) in an environment-controlled (37 C and 5%
CO2) system consisting of an Olympus IX81 inverted microscope (Olympus),
X-Light Multipoint Confocal Scanning Module (CrEST) with Nipkow spinning
disc, and a Hamamatsu C9100-02 CCD camera (Hamamatsu Photonics K.K).
Bright-field images were acquired with a  63 phase contrast objective (NA¼ 1.25
oil, Olympus) and a high-speed shutter system. Fluorescent images were acquired
with a Lumencor SPECTRA-4 LED-based Light Engine Illumination System with
390/18; 475/28; 549/15; 632/22 solid-state LEDs using VisiView Premier Image
acquisition Software. To examine the impact of the CPAF-specific inhibitor peptide
time-lapse videomicroscopy was conducted similarly on a Nikon Ti-E inverted
deconvolution microscope equipped with a Hamamatsu 4.0 4Mp Mono camera,
 40/0.95 Apo DIC W.D. 0.25mm objective, Lumencor Spectra 7 epifluorescent
lamp and climate control chamber. In short, the reporter cells were infected for 2 h
(MOI¼ 0.5), washed and incubated at 37 C and 5% CO2 for either 12 or 24 h.
Media were then replaced with media containing 0, 2.5, 5, 7.5, 10, 12.5, 15, 20,
30 mM CPAF peptide or control peptide. Videomicroscopy was conducted from
24 h p.i. Acute cytotoxicity was observed at CPAF inhibitor peptide concentrations
415 mM. P53-Venus pulses were not observed in infected cells at any of the CPAF-
peptide concentrations tested but cytotoxic effects limited recording times to
between 10 and 20 h. P53 pulses were still evident in uninfected cells cultured in the
presence of the CPAF peptide. The interval between frames was 20min and
exposure times were o50ms to minimize photobleaching and phototoxic effects.
Post-acquisition processing and analysis was conducted using FIJI software.
Infectious progeny assays. HeLa cells seeded in 384-well plates were infected
with CTL2 as described above. Infected cells were lysed at 48 h p.i. by adding
Nonidet P40 (NP40) at a final concentration of 0.06% per well. Pipetting steps were
performed using a robotic station (Biomek FX pipetting robot, Beckman Coulter).
Lysates were diluted in infection medium and were transferred to fresh HeLa cells
at a final dilution of 1:40. After 2 h medium was exchanged. Plates were incubated
for 24 h at 35 C and 5% CO2 and processed for immunolabelling.
Transmission electron microscopy. Samples were fixed with 2.5% glutaraldehyde,
post-fixed with 0.5% osmiumtetroxide, contrasted with 2% uranylacetate and 0.1%
tannic acid, dehydrated with a graded ethanol series and epoxy resin-embedded.
Ultrathin sections were contrasted with lead citrate and analysed using a Leo 906E
transmission electron microscope.
Indirect immunofluorescence. This procedure was conducted as described pre-
viously62. Briefly, cell monolayers were fixed for 25min in 4% paraformaldehyde
followed by liberal washing with PBS. Monolayers were permeabilized for 10min
with Triton X-100 (0.3%) in PBS, washed three times and then incubated with 2.5%
BSA in PBS as a blocking reagent. Cells were sequentially incubated for 1 h at room
temperature (or overnight at 4 C) with primary antibodies and 1 h at room
temperature with secondary antibodies. Samples were then washed with PBS and
mounted onto glass slides using Mowiol.
Apoptosis assay. HeLa cells seeded in 384-well plates were infected with CTL2 as
described in the infectious progeny assay. Cells were treated with Nutlin3a at the
indicated concentrations from 12 h p.i. Ten hours post Nutlin3a treatment,
medium was exchanged and recombinant human TNF-a (BD Pharmingen,
554618) was added at the indicated concentrations with 10 mgml 1 cycloheximide
(Sigma, 065K12261) together with Nutlin3a and incubated for 5 h until fixation
and immunolabelling.
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